A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

Black, Donald W.; Wesner, Robert B.; Bowers, Wayne A.; Gabel, Jenelle

doi:10.1001/archpsyc.1993.01820130046008

Cited by 243 publications

(100 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Superiority to a pill placebo or a psychological placebo was demonstrated in some studies (Barlow et al 2000;Beck et al 1992;Carlbring et al 2006;Klosko et al 1990;Marks et al 1983Marks et al , 1993Murphy et al 1998), while others found no difference to the control condition (Bakker et al 1999;Black et al 1993;Mavissakalian and Michelson 1986;Michelson et al 1988;Shear et al 1994). …”

Section: Monoamine Oxidase Inhibitors (Maoi)mentioning

confidence: 98%

“…Escitalopram is the S-enantiomer of the racemate citalopram; therefore the clinical studies with citalopram may also be relevant for escitalopram (A). Á Fluvoxamine showed efficacy in a number of DBPC studies (Asnis et al 2001;Black et al 1993;de Beurs et al 1995;den Boer and Westenberg 1990;Hoehn-Saric et al 1993;Pols et al 1993). In one study, fluvoxamine and the comparator imipramine were both more effective than placebo and equally effective .…”

Section: Panic Disorder and Agoraphobiamentioning

confidence: 99%

“…In direct comparisons of cognitive behaviour or exposure therapy with psychopharmacological treatment, drugs were superior in three studies (Bakker et al 1999;Black et al 1993;Mavissakalian and Michelson 1986). No differences were found in five studies (Clark et al 1994;Klosko et al 1990;Marks et al 1983;Sharp et al 1997;Telch et al 1985) and an open study (Dannon et al 2004), while one study showed inconsistent results .…”

Section: Monoamine Oxidase Inhibitors (Maoi)mentioning

confidence: 99%

See 2 more Smart Citations

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Monoamine Oxidase Inhibitors (Maoi)mentioning

confidence: 98%

Section: Panic Disorder and Agoraphobiamentioning

confidence: 99%

Section: Monoamine Oxidase Inhibitors (Maoi)mentioning

confidence: 99%

See 1 more Smart Citation

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

show abstract

“…That is, any given therapy tends to do better in comparison with other interventions when it is conducted by people who are expert in its use than when it is not. For example, cognitive therapy for panic has fared better (relative to pharmacotherapy) when it has been implemented by knowledgeable experts ( Clark et al, 1994 ) than when it has not ( Black, Wesner, Bowers, & Gabel, 1993 ). Conversely, differences favoring cognitive therapy over drugs in the treatment of depression found in early comparisons have not been evident in more recent studies that have done a better job of implementing pharmacotherapy in an adequate fashion ( Hollon et al, 1991 ).…”

Section: Investigator Allegiancementioning

confidence: 99%

Defining empirically supported therapies.

Chambless¹,

Hollon²

1998

Journal of Consulting and Clinical Psychology

2,435

1,935

View full text Add to dashboard Cite

A scheme is proposed for determining when a psychological treatment for a specific problem or disorder may be considered to be established in efficacy or to be possibly efficacious. The importance of independent replication before a treatment is established in efficacy is emphasized, and a number of factors are elaborated that should be weighed in evaluating whether studies supporting a treatment's efficacy are sound. It is suggested that, in evaluating the benefits of a given treatment, the greatest weight should be given to efficacy trials but that these trials should be followed by research on effectiveness in clinical settings and with various populations and by cost-effectiveness research.

show abstract

“…Within the TCAs, both imipramine and clomipramine have been studied (Cross National Collaborative Panic Study, Second Phase Investigators, 1992;Papp et al, 1997). The currently available SSRIs citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, and sertraline have all been proven more effective than pill-placebo in reducing symptomatology in PD (Ballenger et al, 1998a;Black et al, 1993;Hoehn-Saric et al, 1993;Lecrubier et al, 1997;Michelson et al, 1998;Rapaport et al, 1998;Sharp et al, 1996;Wade et al, 1997). The daily dosages of these antidepressants are similar to those used in the treatment of major depressive disorder (see Table 1).…”

Section: Pharmacotherapy Of Pdmentioning

confidence: 99%

Evidence-based pharmacotherapy of panic disorder

Batelaan¹,

Balkom²,

Stein³

2012

Essential Evidence-Based Psychopharmacology

View full text Add to dashboard Cite

This paper reviews the literature on the pharmacotherapy of panic disorder, in order to address the questions (1) what is the first-line pharmacotherapy of choice for panic disorder?, (2) for how long should maintenance pharmacotherapy be continued, and (3) what is the optimal approach to the treatmentrefractory patient with panic disorder. A MEDLINE search was undertaken to collate randomized controlled trials of pharmacotherapy in panic disorder. A review of the evidence indicates that SSRIs are currently the first line agent of choice in panic disorder, and that pharmacotherapy should be continued for at least 1 year. There has been relatively little research on the pharmacotherapy of treatmentrefractory panic disorder, and this area requires future attention.

show abstract

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

Cited by 243 publications

References 20 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Defining empirically supported therapies.

Evidence-based pharmacotherapy of panic disorder

Contact Info

Product

Resources

About